#MyPCDream | GivingTuesday 2023
The global GivingTuesday means so much to us. For this one day each year, generous people from over the world are focused on the impact we can make when we come together to support the causes we care about. Causes like finding a cure for PC in our lifetime. This GivingTuesday, will you help spread us the…
PeDRA Conference 2023
PC Project exhibited, networked, and educated pediatric dermatologists, researchers, and medical students at the annual meeting in Atlanta
PCGA0001-2023
Awarded a one-year, $88,200 grant from Pachyonychia Congenita Project. The main problem of patients with PC is the intense pain they feel when walking. This is due to the malfunction of some skin-forming proteins, especially in the soles of the feet. This malfunction is due to errors (mutations) in the instructions carried by the genes…
PCGA0003-2023
Awarded a one-year, $97,500 grant from Pachyonychia Congenita Project. Pachyonychia congenita (PC) is characterized by excessive callus formation which is caused by thickening of the outer layer of the skin, the epidermis. To form the epidermis, the resident cells have to undergo drastic changes to lose a major fraction of their content with the help…
PCGA0004-2023
Awarded a one-year, $100,000 grant from Pachyonychia Congenita Project. The project aims at improving the understanding of the disease mechanisms involved in painful plantar keratoderma in PC patients. It will compare the expression of genes and proteins involved at a global and cellular level. This study will allow to identify the different cell types and…
Atlanta: PC Lunch and Gathering
Members of our community met for several hours to eat, talk, and share encouragement and experiences about living with PC. On Saturday, November 11, 2023, PC Project invited local PC patients and their loved ones to join us for lunch. We were already in town for the PeDRA (Pediatric Dermatology Research Alliance) Conference and could…
Living With Pachyonychia Congenita: Patient Perspectives and Activism
Over the past year, to raise awareness about PC Project and the patients who live with this rare and painful skin condition, PC Project’s Executive Director, Janice Schwartz, was interviewed by two different journals, the Dermatology Times and the Journal of Dermatology Nurses’ Association. Click to read the article in The Dermatology Times called Living…
Continue Reading Living With Pachyonychia Congenita: Patient Perspectives and Activism
Quinoa Harvest & Andean Festival 2023
A Fundraiser for PC near Bryce Canyon National Park PC researcher, Dr. Roger Kaspar, and his family hosted a fun and educational fundraiser for Pachyonychia Congenita (PC) in Panguitch, Utah, a town just outside Bryce National Park. From Dr. Kaspar: In recognition of the harvest of our Panguitch-grown quinoa (many varieties are experimental), we hosted…
DC Patient Gathering
PC Project representatives attended a NIAMS Coalition Meeting in Washington DC in September, and while we were in town, were delighted to gather with PC patients and family members in the area for a brunch, graciously hosted at the home of Barbara Feinstein and PC Project board member Aaron Klein, parents of a PCer, in…
NIAMS Coalition Outreach & Education Meeting 2023
PC Project attended the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Coalition Education & Outreach meeting on September 19, 2023 at the National Institutes of Health (NIH) campus. The meeting provided educational and networking opportunities, especially with key NIAMS directors who oversee research funding. PC Project also presented a poster about our…
Continue Reading NIAMS Coalition Outreach & Education Meeting 2023
PC News Brief Jul-Aug 2023
PC News Brief Vol 18, No. 4Jul-Aug 2023 With all that’s happened in our PC community lately, I wanted to share some realizations I had while cultivating flower beds this summer. In early May, my husband bought a couple of flats of small flowers, not yet bloomed, to plant in the ground around our home.…
Sol-Gel Phase 1 Update
Erlotinib ointment 3.5% and 5% were investigated by Sol-Gel on healthy volunteers in maximal use condition. Following 28 days of daily application all 12 subjects have completed the study. In general both Erlotinib ointment 3.5% and 5% are considered to be well tolerated , no systemic absorption-related adverse events were reported. The following background information…
